Cartesian Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    €33.51M +49.6% -€66.68M -64.8% -199.0% +6.5 pp -€12.56M -71.4% -37.5% +1.6 pp
    €22.39M -76.5% -€189.21M -721.0% -844.9% -8.8 pp -€43.88M +67.4% -196.0% -1.7 pp
    €95.40M +30.2% €30.47M -237.7% 31.9% +0.62 pp -€26.21M -48.7% -27.5% +0.42 pp
    €73.27M +412.6% -€22.12M -62.7% -30.2% +3.8 pp -€51.07M -266.1% -69.7% -2.8 pp
    €14.29M +148.6% -€59.31M +24.4% -415.0% +4.1 pp €30.74M -169.5% 215.1% +9.8 pp
    €5.75M +639.4% -€47.67M -15.3% -829.0% +64 pp -€44.25M -11.8% -769.6% +57 pp
    €777.64K +336.2% -€56.27M +0.0% -7,235.4% +240 pp -€50.19M +13.6% -6,453.7% +180 pp
    €178.26K -97.4% -€56.25M +80.4% -31,556.0% -310 pp -€44.18M +168.6% -24,784.5% -250 pp
    €6.96M +34.5% -€31.18M +43.8% -448.0% -0.29 pp -€16.45M -10.3% -236.3% +1.2 pp
    €5.18M +97.7% -€21.68M +95.5% -418.8% +0.049 pp -€18.34M +71.0% -354.4% +0.55 pp
    €2.62M -€11.09M -423.7% -€10.73M -409.8%

    Notifications